Find A Doctor Profile | VCU Health

Dr. Jennifer L. Myers

Claim this profile

Virginia Commonwealth University/Massey Cancer Center

Studies Pancreatic Cancer
Studies Liver Cancer
9 reported clinical trials
20 drugs studied

Area of expertise

1

Pancreatic Cancer

Jennifer L. Myers has run 3 trials for Pancreatic Cancer. Some of their research focus areas include:

Stage IV
Stage III
Ki-67 positive
2

Liver Cancer

Jennifer L. Myers has run 3 trials for Liver Cancer. Some of their research focus areas include:

Stage IV
Stage III
Ki-67 positive

Affiliated Hospitals

Image of trial facility.

Virginia Commonwealth University/Massey Cancer Center

Image of trial facility.

VCU Massey Cancer Center At Stony Point

Clinical Trials Jennifer L. Myers is currently running

Image of trial facility.

Nivolumab + Standard Treatment

for Stomach and Esophageal Cancer

This phase II/III trial compares the addition of nivolumab to the usual treatment of paclitaxel and ramucirumab to paclitaxel and ramucirumab alone in treating patients with gastric or esophageal adenocarcinoma that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced). A monoclonal antibody is a type of protein that can bind to certain targets in the body, such as molecules that cause the body to make an immune response (antigens). Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Ramucirumab is a monoclonal antibody that may prevent the growth of new blood vessels that tumors need to grow. Paclitaxel is in a class of medications called antimicrotubule agents. It stops cancer cells from growing and dividing and may kill them. Adding nivolumab to ramucirumab and paclitaxel may work better to treat patients with advanced stomach or esophageal cancer.

Recruiting

1 award

Phase 2 & 3

20 criteria

Image of trial facility.

Chemotherapy

for Pancreatic Cancer

This phase II trial studies the effect of capecitabine and temozolomide after surgery in treating patients with high-risk well-differentiated pancreatic neuroendocrine tumors. Chemotherapy drugs, such as capecitabine and temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving capecitabine and temozolomide after surgery could prevent or delay the return of cancer in patients with high-risk well-differentiated pancreatic neuroendocrine tumors.

Recruiting

1 award

Phase 2

15 criteria

More about Jennifer L. Myers

Clinical Trial Related

5 years of experience running clinical trials · Led 9 trials as a Principal Investigator · 2 Active Clinical Trials

Treatments Jennifer L. Myers has experience with

  • Cisplatin
  • Nab-paclitaxel
  • Gemcitabine Hydrochloride
  • Nivolumab
  • Atezolizumab
  • Peposertib

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?

What does Jennifer L. Myers specialize in?

Is Jennifer L. Myers currently recruiting for clinical trials?

Are there any treatments that Jennifer L. Myers has studied deeply?

What is the best way to schedule an appointment with Jennifer L. Myers?

What is the office address of Jennifer L. Myers?

Is there any support for travel costs?

Unbiased Results

We believe in providing patients with all the options.

Your Data Stays Your Data

We only share your information with the clinical trials you're trying to access.

Verified Trials Only

All of our trials are run by licensed doctors, researchers, and healthcare companies.

Terms of Service·Privacy Policy·Cookies·Security